MAGE A3 antigen-specific cancer immunotherapeutic

Immunotherapy
Nir PeledPaul Bunn

Abstract

Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages II and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase II trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.

References

Nov 11, 1992·International Journal of Cancer. Journal International Du Cancer·F BrasseurT Boon
Nov 3, 1995·International Journal of Cancer. Journal International Du Cancer·F BrasseurY Humblet
Mar 15, 1994·International Journal of Cancer. Journal International Du Cancer·P WeynantsT Boon
May 21, 1999·Lancet·A B AlexandroffK James
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Omar EtonRobert S Benjamin
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Oct 31, 2002·Nature Immunology·Hung T Khong, Nicholas P Restifo
Dec 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MarchandG Stoter
Dec 24, 2003·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·W SienelB Passlick
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Djordje AtanackovicSacha Gnjatic
Jun 4, 2004·Expert Opinion on Biological Therapy·Dennis M Klinman
May 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anne BredenbeckPeter Walden
Jun 10, 2005·International Journal of Cancer. Journal International Du Cancer·Wim H J KruitMarie Marchand
Jun 28, 2005·Blood Reviews·Emma MorrisHans Stauss
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoshihiro MiyaharaHiroshi Shiku
Aug 16, 2005·Blood·Willis H Navarro, Lawrence D Kaplan
Sep 2, 2005·Nature·Gerald Willimsky, Thomas Blankenstein
Nov 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ali O GureNasser K Altorki
Sep 22, 2006·Cancer Immunology, Immunotherapy : CII·Xiao-Fei WangBernard Maillère
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Dec 16, 2006·International Reviews of Immunology·Frédéric Lévy, Sara Colombetti
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Djordje AtanackovicSacha Gnjatic
Jun 27, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Penelope A Bradbury, Frances A Shepherd
Jun 11, 2008·Clinical Lung Cancer·Jae KimDavid Jablons

❮ Previous
Next ❯

Citations

Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Angelique W Whitehurst
Jul 16, 2013·Asian Journal of Andrology·Tao ZhouXue-Jiang Guo
Jan 25, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jessica A HemmingerO Hans Iwenofu
Feb 15, 2011·Journal of Biomedicine & Biotechnology·Ming-Yi HoWinnie Yang
May 11, 2011·European Journal of Histochemistry : EJH·T BujasD Tomas
Sep 26, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sojun HoshimotoDave S B Hoon
Feb 2, 2013·Der Internist·M SchlaakP Kurschat
Jan 1, 2013·Journal for Immunotherapy of Cancer·Stefani Spranger, Thomas Gajewski
Oct 29, 2010·Expert Opinion on Biological Therapy·Kewal K Jain
Jul 10, 2012·Surgery·Alexandria P CogdillJennifer A Wargo
May 19, 2012·Seminars in Oncology·Howard L Kaufman
Jun 13, 2012·Biochimica Et Biophysica Acta·Michael Primig
May 29, 2016·Seminars in Diagnostic Pathology·Mark R Wick, Alejandro A Gru
Sep 17, 2010·Pharmaceutical Biology·Ravirajsinh N JadejaA V Ramachandran
Jul 10, 2019·Journal of Experimental & Clinical Cancer Research : CR·Biswajit Das, Shantibhusan Senapati
Apr 3, 2019·Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention·Linda RothmanColin Macarthur
Jul 9, 2020·Scandinavian Journal of Immunology·Anna K Winge-MainElse Marit Inderberg
May 28, 2019·NPJ Precision Oncology·Su Bin LimChwee Teck Lim
Jun 24, 2020·Cancers·Coral García-FernándezSalvador Borrós
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paolo A AsciertoJedd D Wolchok
Sep 2, 2018·Molecular Cancer Research : MCR·Yanding ZhaoChao Cheng
Jan 30, 2021·International Reviews of Immunology·Rupak Dey SarkarNabendu Biswas
Jul 10, 2021·Critical Reviews in Oncology/hematology·Jasmine KaurMing Q Wei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.